Drug Yields 93% Response in TRK-Fusion Pediatric Cancers (CME/CE)

(MedPage Today) -- Larotrectinib is effective, well tolerated in solid tumors
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news